Maria Roussou - Publications

Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.

Journal: American journal of hematology

Published: May 05, 2025

Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: February 05, 2025

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 25, 2025

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG).

Journal: Leukemia & lymphoma

Published: August 14, 2024

VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG).

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 20, 2024

Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 02, 2024

Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma.

Journal: EJHaem

Published: January 02, 2024

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.

Journal: American journal of hematology

Published: December 11, 2023

Thrombotic and bleeding complications in patients with AL amyloidosis.

Journal: British journal of haematology

Published: November 02, 2023

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.

Journal: Diseases (Basel, Switzerland)

Published: July 28, 2023

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.

Journal: International journal of molecular sciences

Published: July 02, 2023

Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.

Journal: British journal of haematology

Published: April 28, 2023